JP2008505148A - B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療 - Google Patents
B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療 Download PDFInfo
- Publication number
- JP2008505148A JP2008505148A JP2007519697A JP2007519697A JP2008505148A JP 2008505148 A JP2008505148 A JP 2008505148A JP 2007519697 A JP2007519697 A JP 2007519697A JP 2007519697 A JP2007519697 A JP 2007519697A JP 2008505148 A JP2008505148 A JP 2008505148A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- nhl
- treatment
- patients
- chemotherapeutic regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58641404P | 2004-07-09 | 2004-07-09 | |
PCT/EP2005/007213 WO2006005477A1 (en) | 2004-07-09 | 2005-07-07 | Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014006916A Division JP6034314B2 (ja) | 2004-07-09 | 2014-01-17 | B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008505148A true JP2008505148A (ja) | 2008-02-21 |
JP2008505148A5 JP2008505148A5 (pt) | 2012-01-26 |
Family
ID=34972426
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007519697A Withdrawn JP2008505148A (ja) | 2004-07-09 | 2005-07-07 | B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療 |
JP2014006916A Active JP6034314B2 (ja) | 2004-07-09 | 2014-01-17 | B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014006916A Active JP6034314B2 (ja) | 2004-07-09 | 2014-01-17 | B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20060029543A1 (pt) |
EP (1) | EP1765399A1 (pt) |
JP (2) | JP2008505148A (pt) |
KR (1) | KR101250127B1 (pt) |
AU (1) | AU2005261923B2 (pt) |
BR (1) | BRPI0513007A (pt) |
CA (1) | CA2568526C (pt) |
IL (1) | IL179636A (pt) |
MX (1) | MX2007000327A (pt) |
NO (1) | NO344366B1 (pt) |
RU (1) | RU2394596C2 (pt) |
WO (1) | WO2006005477A1 (pt) |
ZA (1) | ZA200701158B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8061104B2 (en) | 2005-05-20 | 2011-11-22 | Valinge Innovation Ab | Mechanical locking system for floor panels |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
AU2011215900A1 (en) | 2010-02-10 | 2012-07-26 | Immunogen, Inc. | CD20 antibodies and uses thereof |
US11055552B2 (en) * | 2016-01-12 | 2021-07-06 | Disney Enterprises, Inc. | Systems and methods for detecting light signatures and performing actions in response thereto |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001010974A (ja) * | 1992-11-13 | 2001-01-16 | Idec Pharmaceuticals Corp | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US20030206903A1 (en) * | 1998-08-11 | 2003-11-06 | Idec Pharmaceuticals Corporation | Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
BRPI0009448B8 (pt) * | 1999-04-01 | 2021-05-25 | Univ Texas | kit para uso no tratamento de uma neoplasia em um mamífero |
KR20020091170A (ko) * | 2000-03-31 | 2002-12-05 | 아이덱 파마슈티칼즈 코포레이션 | B 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-cd20의 조합된 사용 |
WO2003068821A2 (en) * | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
WO2004047612A2 (en) | 2002-11-22 | 2004-06-10 | Nuvelo, Inc. | Methods of therapy and diagnosis |
-
2005
- 2005-07-07 RU RU2007104839/14A patent/RU2394596C2/ru not_active IP Right Cessation
- 2005-07-07 KR KR1020077000190A patent/KR101250127B1/ko active IP Right Grant
- 2005-07-07 MX MX2007000327A patent/MX2007000327A/es active IP Right Grant
- 2005-07-07 JP JP2007519697A patent/JP2008505148A/ja not_active Withdrawn
- 2005-07-07 WO PCT/EP2005/007213 patent/WO2006005477A1/en active Application Filing
- 2005-07-07 CA CA2568526A patent/CA2568526C/en active Active
- 2005-07-07 BR BRPI0513007-7A patent/BRPI0513007A/pt not_active Application Discontinuation
- 2005-07-07 AU AU2005261923A patent/AU2005261923B2/en active Active
- 2005-07-07 EP EP05761149A patent/EP1765399A1/en not_active Withdrawn
- 2005-07-08 US US11/176,671 patent/US20060029543A1/en not_active Abandoned
-
2006
- 2006-11-27 IL IL179636A patent/IL179636A/en active IP Right Grant
-
2007
- 2007-02-08 ZA ZA200701158A patent/ZA200701158B/xx unknown
- 2007-02-08 NO NO20070763A patent/NO344366B1/no unknown
-
2014
- 2014-01-17 JP JP2014006916A patent/JP6034314B2/ja active Active
-
2018
- 2018-05-14 US US15/978,460 patent/US20190112383A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001010974A (ja) * | 1992-11-13 | 2001-01-16 | Idec Pharmaceuticals Corp | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US20030206903A1 (en) * | 1998-08-11 | 2003-11-06 | Idec Pharmaceuticals Corporation | Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody |
Non-Patent Citations (4)
Title |
---|
JPN6011046570; 設楽研也: '分子生物学的研究に立脚した新規治療法 『抗体工学の進歩と癌治療』' 医学のあゆみ Vol.199,No.9, 20011201, P.663-667 * |
JPN6011046571; 飛内賢正: '特集 -造血器腫瘍の新しい分子標的療法- 『1 新規抗体療法の開発 (4)放射性同位元素標識抗CD20抗' 血液・免疫・腫瘍 Vol.8,No.3, 20030715, P.251-256 * |
JPN6012041416; Rambaldi,A. et al.: 'Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients wit' Blood Vol.99,No.3, 20020201, P.856-862 * |
JPN6012041420; 飛内賢正: '『Radioimmunotherapy』-131Iあるいは90Yを抱合したマウス型抗CD20抗体によ' 医学のあゆみ Vol.202,No.1, 20020706, P.75-80 * |
Also Published As
Publication number | Publication date |
---|---|
NO20070763L (no) | 2007-02-08 |
BRPI0513007A (pt) | 2008-04-22 |
KR101250127B1 (ko) | 2013-04-02 |
CA2568526A1 (en) | 2006-01-19 |
IL179636A (en) | 2013-09-30 |
EP1765399A1 (en) | 2007-03-28 |
ZA200701158B (en) | 2008-09-25 |
NO344366B1 (no) | 2019-11-18 |
KR20070042527A (ko) | 2007-04-23 |
RU2007104839A (ru) | 2008-08-20 |
JP6034314B2 (ja) | 2016-11-30 |
MX2007000327A (es) | 2007-03-12 |
US20190112383A1 (en) | 2019-04-18 |
CA2568526C (en) | 2015-11-03 |
AU2005261923A1 (en) | 2006-01-19 |
IL179636A0 (en) | 2007-05-15 |
WO2006005477A1 (en) | 2006-01-19 |
US20060029543A1 (en) | 2006-02-09 |
AU2005261923B2 (en) | 2010-11-18 |
JP2014080429A (ja) | 2014-05-08 |
RU2394596C2 (ru) | 2010-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
JP6034314B2 (ja) | B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療 | |
ES2563439T5 (es) | Medios y métodos para tratar LDCBG | |
JP2004512262A5 (pt) | ||
JP2022536511A (ja) | 癌の処置のための併用療法での活性化可能抗pdl1抗体および抗ctla-4抗体の使用 | |
ES2328159T3 (es) | Inmunoglobulinas anti-epcam. | |
KR20220153681A (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
JP7316120B2 (ja) | 腫瘍性疾患のための治療 | |
Maraveyas et al. | Pharmacokinetics and toxicity of an yttrium‐90‐citc‐dtpa‐hmfg1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer | |
JP2022523740A (ja) | Ror1抗体イムノコンジュゲートによる癌の治療 | |
WO2014142220A1 (ja) | 抗腫瘍剤 | |
Zeng et al. | Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma | |
Zeng et al. | Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131 I-anti-HCC mAb. Phase I/II clinical trials | |
Coffey et al. | Therapy of non-Hodgkin's lymphoma | |
Riva et al. | Locoregional immunotherapy of human ovarian cancer: preliminary results | |
WO2004000216A2 (en) | Anti-tenascin antibody fragments and minibodies for treatment of lymphoma | |
Colleoni et al. | Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors | |
DeNardo et al. | Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6 | |
Chen et al. | Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma | |
Furman et al. | Testicular relapse in children with acute nonlymphoblastic leukemia | |
RU2739107C1 (ru) | Способ диагностики рака желудка с гиперэкспрессией Her2/neu | |
CN110151987B (zh) | 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途 | |
Al-Tweigeri | Fam-Trastuzumab Deruxtecan (Enhertu) Induced pyloric perforation in hormonal receptor positive/HER2 low express metastatic breast cancer. | |
Sayre et al. | Extramedullary plasmacytoma: angiographic findings | |
WO2023159102A1 (en) | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080613 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080613 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111202 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20111202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121106 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130118 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130917 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20150821 |